scholarly journals Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Lotte Van Der Weijst ◽  
Veerle Surmont ◽  
Wim Schrauwen ◽  
Yolande Lievens
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Visual Memory ◽  
Patient Reported Outcomes ◽  
Post Treatment ◽  
Lung Cancer Patients ◽  
Systemic Treatments ◽  
Patient Reported ◽  
The Impact ◽  
Over Time

IntroductionThis report investigates the impact of systemic treatments (chemotherapy or immunotherapy) with(out) loco-regional radiotherapy, on HRQoL, toxicity and neurocognitive functioning (NCF) in locally advanced and metastatic non-small cell lung cancer patients enrolled in the PRO-Long study.Materials and MethodsData on patient-reported HRQoL and fourteen toxicities was collected, while NCF was tested, up to one-year post-treatment. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30. Lung cancer, treatment and neuro-psychological related toxicities were scored with the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. NCF was evaluated with six neurocognitive tests. Mixed model analyses were conducted to determine statistical significance (p = .01). Meaningful clinical important differences (MCIDs) were applied for changes in HRQoL and NCF data, while toxicities were compared to baseline values.ResultsIn total, 50 patients were enrolled. Overall HRQoL (p = .357) nor its domains (physical, p = .643; role, p = .069; emotional, p = .254; cognitive, p = 494; social, p = .735) changed significantly over time. Meaningful improvements in overall HRQoL were seen in 22, 38 and 39% and deteriorations in 22, 5 and 28% of patients at 2–3, 6 and 12 months respectively post-treatment. Overall toxicity (p = .007), lack of appetite (p = .001), nausea (p = .004) and dysphagia (p = .000) significantly decreased over time. Treatment caused acute toxicity, such as dyspnoea (45%) and memory problems (42%), but also alleviated pre-existing symptoms, including lack of appetite (32%), anxiety (29%) and depression (28%) at 2/3 months. The NCF domains of visual memory (p = .000) and cognitive processing speed (p = .000) showed significant improvements over time. In terms of MCIDs, at 2–3 months (18%) and 6 months (15%), verbal memory was particularly impacted; at 12 months, visual memory (18%) and executive function (18%) deteriorated primarily.ConclusionThe results suggest that therapy has no significant negative impact on overall HRQoL, its domains, and NCF. About one-third of patients reported a meaningful improved HRQoL at 1 year post-treatment. Treatment caused toxicity, but also alleviated pre-existing symptoms.

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

2019 ◽  
Vol 28 (4) ◽  
pp. 1809-1816
Author(s):  
Johnny M. Hoang ◽  
Navneet Upadhyay ◽  
Dozie N. Dike ◽  
Jaekyu Lee ◽  
Michael L. Johnson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Patient Reported Outcomes ◽  
Lung Cancer Patients ◽  
Patient Reported ◽  
Treatment Naïve

Characterizing biomarker testing over time in lung cancer patients using oncology electronic medical records (EMR).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20056-e20056
Author(s):  
Jennifer Christian ◽  
Joe Wagner ◽  
Gregory Mastrogiovanni ◽  
Andrew David Norden ◽  
Ian Kurashige
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Stage Iv ◽  
Lung Cancer Patients ◽  
Anaplastic Lymphoma ◽  
Biomarker Testing ◽  
Nsclc Patients ◽  
The Impact ◽  
Over Time

e20056 Background: This study characterizes biomarker testing over time in Non-Small Cell Lung Cancer (NSCLC) patients treated within a clinical setting. There have been tremendous advances in treatments for NSCLC that target specific biomarkers such as epithelial growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and the Programmed cell death-ligand 1 (PD-L1) pathway. As we consider using oncology EMR records for future studies, it is critical to understand the extent to which biomarker testing is conducted in routine care, the extent to which testing has increased, and the types of patients for which it is done. Methods: This is a retrospective observational analysis derived from the COTA Oncology EHR database from January 1, 2015 through December 31, 2017. The data sets generated for the study included all relevant, retrospective patient-level, de-identified data available for patients with lung cancer, including EGFR, ALK, and PD-L1 testing regardless of age, gender, and stage at diagnosis. We examined characteristics associated with each type of test received as well as by those who had received all 3 biomarker tests, 1-2 of the tests, or no biomarker testing. Analyses were conducted using SAS V. 9.1 and stratified by data source. Results: There were 1,891 patients in the COTA database. Among newly diagnosed NSCLC patients, EGFR testing has been consistently conducted in patients during the study period (76 – 86%), while ALK testing [44% in 2015Q1 to 74% in 2017Q4] and PD-L1 testing [12% in 2015Q1 to 77% in 2017Q4] have steadily increased each quarter. Overall, testing was more likely to be conducted in non-squamous cell lung cancer patients, Stage IV lung cancer, and those without a history of smoking. For EGFR, testing was more prevalent among women and young age groups ( < 64 years vs. 65 and older). Conclusions: Biomarker testing has rapidly increased for ALK and PD-L1, which correlates with the uptake of new targeted therapies. Further research could be conducted to understand clinical outcomes associated with this increase in testing as well as the impact on healthcare resource utilization.

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 10111-10111
Author(s):  
Johnny Hoang ◽  
Navneet Upadhyay ◽  
Dozie N Dike ◽  
Jaekyu Lee ◽  
Charles S. Cleeland ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Patient Reported Outcomes ◽  
Lung Cancer Patients ◽  
Patient Reported ◽  
Treatment Naïve

scholarly journals Electronic Patient Reported Outcomes significantly improved toxicity data collection and were acceptable to both patients and clinicians in lung cancer radiotherapy outpatient clinics.

2017 ◽  
Vol 5 (2) ◽  
pp. 178
Author(s):  
Annalie Shears ◽  
Matthew Barker-Hewitt ◽  
Neil Bayman ◽  
Margaret Harris ◽  
Kate Haslett ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Data Collection ◽  
Clinical Data ◽  
Patient Reported Outcomes ◽  
Toxicity Data ◽  
Cancer Radiotherapy ◽  
Lung Cancer Patients ◽  
Learning Techniques ◽  
Patient Reported ◽  
The Impact

Rationale: Toxicity after radiotherapy for lung cancer can be considerable and yet varies significantly between patients. In the future, it is hoped rapid learning techniques will be used to create decision support systems  that can determine individual patients’ outcomes and so help guide treatment choices accordingly. However, such research relies on the robust collection of prospective toxicity data. Electronic Patient Reported Outcomes (e-PROs) tools are an effective way of improving the quality and quantity of clinical data collection, yet there are currently none in routine use in UK lung cancer patients. Methods: An e-PRO tool was designed to evaluate toxicity after lung cancer radiotherapy in outpatients at the Christie Hospital, Manchester, UK. Patients completed the e-PRO form on a tablet computer prior to consultation and both patients and clinicians completed feedback forms. e-PRO data was uploaded in real time to the electronic patient record. Subsequently, we evaluated the feasibility and acceptability of the use of the e-PRO tool and compared the completeness of toxicity recording with and without e-PROs. Results: Eighty-seven patients completed e-PRO forms with 74 providing feedback. One hundred percent of patients were happy to complete e-PRO forms, 78.2% found the tablet easy to use and  71.5% felt that filling out e-PROs stimulated them to think of issues to discuss with the doctor. Sixty-eight feedback forms were returned by clinicians. One hundred percent used the PRO form and found it helpful, with 79.5% agreeing that it altered their consultation. The records of 38 patients who completed the e-PRO form were evaluated, this was a significant (p=0.0005) difference in toxicity recorded with and without the e-PRO form. Conclusion: e-PROs are acceptable to patients and clinicians and improve the quality and quantity of clinical data collection. Future larger studies will need to validate these findings and assess the impact e-PROs have on decision-making and outcomes.

Sign in / Sign up

Export Citation Format

Share Document